Aurinia Pharmaceuticals Inc (AUPH) News
Filter AUPH News Items
AUPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest AUPH News From Around the Web
Below are the latest news stories about AURINIA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AUPH as an investment opportunity.
Exploring Three High Growth Tech Stocks In The United StatesOver the last 7 days, the United States market has remained flat, yet it is up 30% over the past year with earnings forecasted to grow by 15% annually. In this context of robust growth potential, identifying high growth tech stocks that align with these positive trends can be key for investors seeking opportunities in an evolving market landscape. |
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock OptionsInvestors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately. |
While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownershipKey Insights The considerable ownership by retail investors in Aurinia Pharmaceuticals indicates that they collectively... |
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus NephritisROCKVILLE, Md. & EDMONTON, Alberta, November 18, 2024--Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis |
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024ROCKVILLE, Md. & EDMONTON, Alberta, November 15, 2024--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence (ACR) 2024 taking place in Washington, D.C., November 14-19. The data highlight the need for additional screening for lupus nephritis (LN), a serious manifestation of systemic lupus erythematosus (SLE), and reinforce the clinical importance of LUPKYNIS® (v |
Aurinia to Participate in Jefferies London Healthcare ConferenceROCKVILLE, Md. & EDMONTON, Alberta, November 14, 2024--Aurinia to Participate in Jefferies London Healthcare Conference |
Aurinia slashes workforce by 45% to focus on lupus and autoimmune assetsAurinia has announced a 45% workforce reduction to bolster sales of the lupus drug Lupkynis and advance the development of AUR200. |
Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...Aurinia Pharmaceuticals Inc (AUPH) reports significant revenue increases and patient growth, while implementing cost-saving measures through workforce reduction. |
Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat EstimatesAurinia (AUPH) delivered earnings and revenue surprises of 400% and 14.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Aurinia: Q3 Earnings SnapshotThe Edmonton, Alberta-based company said it had profit of 10 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 2 cents per share. |